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ABSTRACT 
Objective: Moringa oleifera is a medicinal plant species that has potential as an antidiabetic. The present study was designed to evaluated 
molecullar mechanism antidiabetic ethyl acetate fraction of Moringa oleifera leaves (EAFML). 
Methods: The study was conducted on 30 male wistar rats which were induced with the combination of streptozotocin and nicotinamide by 
intraperitoneal administration to make a model of type 2 diabetes. After the diabetic induction, all rats were divided into six group and once daily 
administered orally EAFML in doses standardized quercetine. The treatment was given for ten days, and on the final treatment, all rats were 
checked their blood glucose level and lipid profile. The skeletal muscles and liver were taken to examine glucose transporter-4 (GLUT4) expression 
by immunohistochemistry.  
Results: The result of this study shows that the blood glucose level in diabetic rats with the treatment of EAFML decreased significantly from 
355.8±83.7 mg/dL to 177.5±89.3 mg/dL. The cholesterol decreased significantly from 105.2±47.4 mg/dL to 58.6±6.9 mg/dL and low-density 
lipoprotein (LDL) in diabetic rats with the treatment of EAFML decreased significantly compared to control group from 175.6±41.9 mg/dL to 
95.3±8.0 mg/dL. The expression of GLUT4 in skeletal muscles increased from 0.7±1.0 to 3.9±1.1 and in the liver increased significantly from 1.8±1.3 
to 2.9±1.9.  
Conclusion: The EAFML can decrease blood glucose level, cholesterol and low-density lipoprotein in type 2 diabetic rat model. Other than that, this 
fraction can improve insulin sensitivity by the increase of GLUT4 expressions. 
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Type 2 diabetes is a progressive disease characterized by 
hyperglycemia with insulin resistance in early condition. Insulin 
resistance is a reduction of the response of insulin target cells and 
tissues to a physiological concentration of insulin. This condition is 
caused by abnormalities of metabolism such as metabolic stress 
syndrome, obesity, high blood pressure, high blood lipids, high blood 
uric acid and diabetes [1]. Type 2 diabetes with insulin-resistant 
especially marked by a defect in glucose uptake because it 
associated with regulation of GLUT4 protein. The expression of 
GLUT4 gene is subject to both tissue-specific and hormonal/ 
metabolic regulation. GLUT4 plays a critical role in glucose-sensing 
although only 15% of the blood glucose is absorbed by adipose 
tissue and the remaining (85%) by muscle in healthy individual [2]. 
Insulin induces translocation of GLUT4 from intracellular vesicles to 
the plasma membrane, which permits the facilitated diffusion of 
circulating glucose down its concentration gradient into muscle cells 
leading to a rapid increase in the uptake of glucose. Accumulating 
evidence indicates that either expression deregulation or functional 
impairment of GLUT4 can cause insulin resistance. Because of its 
crucial role, GLUT4 has been considered to be a potential 
therapeutic target for type 2 diabetes [3].  
Some plants are shown to have antidiabetic effects, one of which is 
Moringa oleifera leaves [4]. Moringa oleifera is a medicinal plant 
species that has potential as an antidiabetic [5]. Moringa oleifera is 
rich in phytochemical compounds such as flavonoids, alkaloids, and 
saponins [6]. Flavonoid is one of the biologically active class of 
secondary metabolite plant compounds that belong to an important 
part of human diet. The antidiabetic properties of flavonoids are 
mainly through their effect on a number of molecular targets and 
regulation of several pathways such as reducing apoptosis, 
improving proliferation of pancreatic beta cell and promoting 
insulin secretion, regulation of glucose metabolism in hepatocytes 
and subsequent improvement of hyperglycemia, decreasing insulin 
resistant, inflammation and oxidative stress in adipocytes and 
skeletal myofibers, enhancing glucose uptake in skeletal and adipose 
tissues [2]. 
Based on these reviews, Moringa oleifera leaves have the potential to 
be developed as an antidiabetic agent. However, it is not yet known 
whether the active component has an effect as an antidiabetic and 
molecular mechanism. Thus, it is important to study the antidiabetic 
effect of EAFML and molecular mechanism study. 
MATERIALS AND METHODS 
Material 
Streptozotocin (STZ) was purchased from Nacalai tesque, INC (Kyoto, 
Japan), Nicotinamid (Sigma-Aldrich, USA). Glucose level was measured 
by using colorimetric metode (GOD-PAP) with glucose oxidase and 4-
aminoantipyrine (DiaSys, Diagnostic System GmbH, Holzheim, 
Germany). Lipid profile was measured by enzimatic photometric 
methods using kit from DiaSys, Diagnostic System GmbH, Holzheim, 
Germany. Antibodies for determining of GLUT4 expression were a 
primary anti-GLUT4 antibody (Santa Cruz Biotechnology, California, 
USA). All other reagents were high-grade qualified material. 
Preparation of EAFML 
Moringa oleifera leaves were collected from the area of Gunung Kidul, 
Yogyakarta special region, Indonesia. The leaves were shade dried, 
powdered and store in airtight container for further use. The plant was 
authenticated with certificate number 029/lab. Bio/B/III/2017 by a 
botanist at the Department of Biology Pharmacy, Faculty of Pharmacy, 
Ahmad Dahlan University, Indonesia. The dried powder of Moringa 
oleifera leaves was subjected to extractor by maceration using 80% 
ethanol for 3 d and was re-extracted using the same solvent for 4 d. All 
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liquid extracts were collected and concentrated using a rotary vacuum 
evaporator under reduced pressure. The extract fractionated with n-
hexane and the water-soluble fraction is purified with ethyl acetate 
and obtained ethyl acetate fraction. 
Preparation of type 2 diabetic rat model 
The animal model handling protocols of this study were in accordance 
with the guidelines of the animal care of the Departement of 
Pharmacology, Faculty of Pharmacy, Ahmad Dahlan University, 
Indonesia. 30 male wistar rats were acclimatized for 1 w and housed in 
individual cages at a constant temperature (22±2 °C) with a constant 
relative humidity (55±10%), controlled lighting 12:12h light-dark cycle 
(light on at 6:00 a. m) and had free access to food and water ad libitum. 
The rats were previously exited before being induced fasted with 
administering nicotinamide 100 mg/kg insulin solution by 
intraperitoneal (i. p). 15 min followed by injection of STZ in doses of 65 
mg/kg (i. p) in 0.1 M buffer citrate, pH 4.5 made new. The control group 
was injected with a citrate buffer. After 5 d, the animal was measured for 
their fasting blood glucose level (BGL). BGL ≥ 200 mg/dL fall into the 
positive category of diabetes. The methodology of this experiment was 
performed after the approval by Research Ethics Committee Ahmad 
Dahlan University with ethical approval number 021703005. 
Antidiabetic treatment of EAFML 
A total of 30 rats were used and divided into 6 groups with 5 rat per 
group. Group I (control, a healthy rat). Group II (negative control, an 
untreated diabetic rat). Group III (positive control, a diabetic rat 
with metformin treatment in doses of 100 mg/kg once daily orally). 
Group IV, V and VI (treatment groups 1, 2 and 3, a diabetic rat with 
EAFML treatment in doses of 12.5; 25 and 50 mg/kg once daily 
orally). Treatment was carried out for 10 d. On the 10th day, all the 
rats were fasted and measured their BGL and lipid profile. 
Histology of skeletal muscle and liver 
The rats were sacrificed at the end of the treatment and the skeletal 
muscle and liver tissue of control and treated groups were taken and 
fixed with 4% formaldehyde in phosphate buffer. The tissues were 
embedded in paraffin and cut into pieces of the desired size and then 
the tissues were deparaffinized in xylane then dehydrated of alcohol 
concentration. The sections were then stained with Hematoxylin-
Eosin (HE) and observed using a light microscope with a 
magnification of 1000x. 
Expression of GLUT4 by immunohistochemistry  
Sections of skeletal muscle and liver organ were collected and fixed 
with 4% formaldehyde solution in the phosphate-saline buffer for 
more than 2 h. Then the tissue was hydrated with concentrated 
alcohol, then cleaned using xylol. The tissue was immersed in 
paraffin and cut with a thickness of 4 μm and placed on a glass slide. 
Endogenous peroxidase activity in the tissue was blocked with 3% 
H2O2 in methanol for 15 min and washed with aqua dest. The tissue 
portion was incubated with 20% horse serum for more than 10 min, 
subsequently reincubated with GLUT-4 primary antibody with 1: 
250 dilution for one hour at room temperature, followed by 
incubation peroxidase-conjugate secondary antibody with 1: 500 
dilution for 1 hour. Visualization was performed after incubation 
with the substrate for 15 min, and the section was counterstained 
with Hematoxylin for 30 min, hydrated with alcohol and xylene. The 
evaluation of protein expression was calculated based on 
semiquantitative methods according to the modified Remmele 
method. Immunoreactive score (IRS) or Rammele scale index is the 
result of multiplication between the percentage score of 
immunoreactive cells with color intensity score on immunoreactive 
cells. The end result obtained ranges from 0-12 points [7]. 
Statistical analysis  
Statistical analysis used SPSS 17.0 with a confidence level of 95%. 
The date from an examination of blood glucose level and lipid profile 
was presented in chart table, then it’s was normalitis tested by using 
sapiro-wilk, and the homogenity was tested by using Leven’s Test of 
Homogeneity of Varian test. The average difference of each 
component was analyzed statistically by one-way ANOVA. 
Differences of GLUT4 expression between groups were analyzed 
with the Kruskal-Wallis test and followed by Mann-Whitney test. 
RESULTS 
Observation of blood glucose level in pre-treatment 
On day-1, the rats were injected intraperitoneally with 
nicotinamide in doses of 100 mg/kg in normal saline. After 15 min, 
the rats were given an intraperitoneal injection with STZ in doses 
of 65 mg/kg. bw in citrate buffer to induce diabetes. BGL was 
measured on day-5. Rats with diabetes were those that have 
BGL>200 mg/dL [2]. The data of BGL before and after induction 
can be seen in table 1. 
 
Tabel 1: Blood glucose level in pre-treatment 
Group  Ʃ Blood glucose level (mg/dL) 
H-1 H-5 
Control  5 64.7±11.7 105.0±13.5 
Diabetes  25 70.1±11.7 493.5±122.9* 
 *
 
Data of BGL on day-5 significantly different from day-1 (p<0.05), Data represent mean±SD 
The BGL of induced rats on day-5 increased significantly from 
70.1±11.7 mg/dL to 493.5±122.9 mg/dL with p<0.05. It showed that 
the combination of nicotinamide injection and STZ injection was 
able to improve BGL significantly compared with the control group 
on day-5. 
Observation of BGL in post-treatment 
After diabetes induction using the combination of STZ dan 
nicotinamide, the diabetic rats divided into 5 groups and given 
treatment for 10 d. On day-11 of post-treatment, the rats’ BGL were 
checked. The result of BGL in post-treatment is presented in table 2. 
 
Tabel 2: Blood glucose level in post-treatment 
Groups  Blood glocose level of post-treatment (mg/dL) 
Control  84.1±18.7 
Diabetes  355.8±83.7* 
Diabetes+metformin 100 mg/kg 258.8±175.9* 
Diabetes+EAFML 12.5 mg/kg 313.2±19.5* 
Diabetes+EAFML 25 mg/kg 337.2±124.2* 
Diabetes+EAFML 50 mg/kg 177.5±89.3 
*significantly different from the control group with p<0.05, Data represent mean±SD 
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Table 2 shows there are no significant differences between the BGL 
of diabetic rats with EAFML treatment in doses of 50 mg/kg for 10 d 
and the BGL of the healthy group. It shows that the administration of 
EAFML in doses of 50 mg/kg improved BGL significantly. 
Observation of lipid profile in post-treatment 
Lipid profile observations were performed on day-11 of post-
treatment. The lipids that were analyzed included cholesterol, 
triglycerides, LDL and HDL. Lipid profile data can be seen in table 3. 
 
Table 3: Lipid profile in post-treatment 
Groups  Lipid profile (mg/dL) 
Cholesterol TG LDL HDL 
Control 75.0±7.3 62.2±19.6 134.2±11.7 71.7±9.1 
Diabetes  105.2±47.4 51.0±22.1 175.6±41.9 80.6±18.0 
Diabetes+metformin 72.8±10.6 52.0±9.3 133.7±20.8 71.3±11.6 
Diabetes+EAFML 12.5 mg/kg 73.4±23.1 57.2±13.7 124.5±40.5 62.5±15.7 
Diabetes+EAFML 25 mg/kg 58.6±6.9 * 65.0±14.9 95.3±8.0 * 49.7±3.0 * 
Diabetes+EAFML 50 mg/kg 73.0±13.3 36.4±11.3 134.3±29.3 68.6±15.0 
*
 
significantly different from the diabetic group with p<0.05, data represent mean±SD 
Based on observation of lipid profile in post-treatment, it can be 
seen that the diabetic group with administration of EAFML in 
doses of 25 mg/kg is significantly different from the diabetic 
group. This shows that the administration of EAFML in doses of 25 




Fig. 1: Cross-section of skeletal muscle tissues with HE staining in 1000x magnification, (A) Control; (B) Diabetes; (C) 
Diabetes+metformin; (D) Diabetes+EAFML 12.5 mg/kg; (E) Diabetes+EAFML 25 mg/kg; (F) Diabetes+EAFML 50 mg/kg 
 
 
Fig. 2: Cross-section of liver tissues with HE staining at 1000x magnification, (A) Control; (B) Diabetes; (C) Diabetes+metformin; (D) 
Diabetes+EAFML 12.5 mg/kg; (E) Diabetes+EAFML 25 mg/kg; (F) Diabetes+EAFML 50 mg/kg 
 
Histology of skeletal muscle and liver tissue 
Based on histologic observation with HE staining from cross-section 
of skeletal muscle and liver organs of rats as seen in fig. 1 and fig. 2, 
it was obtained that in normal rats the cell nuclei and hepatocytes 
are intact and clear ( ), whereas in diabetic rats the cell nuclei had 
undergone necrosis which is indicated by less clear and non-intact 
cell shapes. After administration of EAFML in doses of 12.5 mg/kg; 
50 mg/kg and 50 mg/kg, it can be seen that the cell nuclei had 
improved, in which the number of cell nuclei that were intact and 
that had clear color increased. 
GLUT4 expression in skeletal muscle and liver 
Molecular observation had been undergone to see the expression of the 
GLUT4 protein on skeletal muscle and liver organs using 
immunohistochemistry method. GLUT4 is one of the parameters of the 
occurrence of insulin resistance. Changes of GLUT4 protein level which 
influenced glucose tolerance have been proven on a transgenic animal 
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with GLUT4 protein deficiency and play roles in insulin resistance 
condition; thereby, therapy with a target on the increase of GLUT4 
protein expression is a new breakthrough in discovering a new 
antidiabetic medication [8]. 
The observations were performed under a light microscope with 
400x magnification. If in cells there is found GLUT4 protein 
expression, the brown color will be seen on the cytoplasm. Mayer 
Hematoxylin was used as a counterstain for examination of GLUT4. 
Immunohistochemical features for GLUT4 protein expression can 
be seen in fig. 3 and 4. 
The observation result of immunohistochemical of GLUT4 protein in 
muscle and liver can be seen in table 4. 
 
Table 4: Expression of GLUT4 in skeletal muscle and liver in post-treatment 
Groups  GLUT4 expression 
Skeletal muscle Liver  
Control 3.4±2.3* 4.5±2.3* 
Diabetes  0.7±1.0 1.8±1.3 
Diabetes+metformin 2.6±1.6* 1.0±0.7 
Diabetes+EAFML 12.5 mg/kg 2.2±1.0* 1.3±1.5 
Diabetes+EAFML 25 mg/kg 2.2±1.5* 3.6±1.9* 
Diabetes+EAFML 50 mg/kg 3.9±1.1* 2.9±1.9* 
*
 
significantly different from the diabetic group with p<0.05, Data represent mean±SD 
 
Fig. 3: Immunohistochemical staining results of experimental animals’ skeletal muscle tissues using GLUT-4 antibody, (A) Control; (B) 




Fig. 4: Immunohistochemical staining results of experimental animals’ liver tissues using GLUT-4 antibody, (A) Control; (B) Diabetes; (C) 
Diabetes+metformin; (D) Diabetes+EAFML 12.5 mg/kg; (E) Diabetes+EAFML 25 mg/kg; (F) Diabetes+EAFML 50 mg/kg; Magnification 400x 
 
Based on fig. 3. Immunohistochemical Results, GLUT4 expression is 
indicated by dark brown spots ( ). From the pictures ,it can be seen 
that from the administration of EAFML at the dosage of 12.5 mg/kg; 
50 mg/kg and 50 mg/kg, GLUT4 expression increased which was 
indicated by the increased of the number of brown color and the 
color is more dense. 
DISCUSSION 
In this study, type 2 diabetes induction was done to make the 
combination of STZ and nicotinamide. Induction of STZ and 
nicotinamide in rat model of type 2 diabetes is based on the 
protective effects of nicotinamide against β-cytotoxic effects of STZ. 
This model is as a model for non-obese type 2 diabetes [9]. 
Based on this study, it showed that the ethyl acetate fraction of 
Moringa oleifera leaves has potential as antidiabetic agent. Several 
studies related to the effects of Moringa oleifera leaves as 
antidiabetes have been performed. The observation of in vitro assay 
with clonal of pancreatic beta cells of BRIN-BDII showed that 
acetone extract of Moringa oleifera leaves had an insulinotropic 
effect through KATP-dependent pathway indicated by the increased 
Hidayati et al. 





level [10]. Another in vivo study proved that 
Moringa oleifera leaves extract significantly increased the activity of 
superoxide dismutase (SOD) and glutathione-s-transferase (GST), 
and decreased lipid peroxidase (LPO), which is a characteristic 
factor in chronic diabetes [11]. The antidiabetic evaluation of 
methanol extract of Moringa oleifera leaves was proven can decrease 
blood glucose levels of rat and showed antioxidant activity with the 
decreased the level of nitric oxide (NO) serum [12]. Another study 
also suggested that water extract of Moringa oleifera leaves had a 
hypoglycemic effect through normalization of the increase of hepatic 
pyruvate carboxylase enzyme and regeneration of hepatocyte and 
pancreatic beta cells damages [13]. 
The result of phytochemicals Moringa oleifera leaves are polyphenols, 
flavonoids, saponins and alkaloids [14]. Another study suggested that 
the phytochemical content of Moringa oleifera leaves includes: 4-(4'-o-
acetyl-alpha-ramnopiranoyloxy) benzyl isothiocyanate, benzyl 
isothiocyanate [15], total polyphenols, quercetin, kaempferol, and 
lutein [16], quercetin-3-glycosides (isoquersitrin), quercetin-4-
glycosides (spiraeosid), chlorogenic acid [17]. 
These regulation of flavonoids as antidiabetic in many cases may be 
direct i.e. mediated by the physical interaction of a receptor (specific 
enzyme) and the flavonoid compound and may lead to either 
inhibition or activation of the catalytic function of the enzyme. In 
addition, natural polyphenols show less specific antioxidant ability 
of hydroxyl groups linked to aromatic carbon rings [2]. 
In this study, immunohistochemical tests were performed to see 
GLUT4 expression. The GLUT4 expression spread to the skeletal 
muscle, adipose tissue, liver, kidney, and pancreas [18]. In the basal 
condition, GLUT4 is mostly located in intracellular organelles and in 
order to move to the surface of the cell membrane, requires a signal 
from insulin. The expression of some forms of glucose transporter on 
the surface of the cell plays a role in glucose uptake, signal 
regeneration, and metabolism to maintain the body's cellular 
metabolic integrity [19]. This study found that administration of 
EAFML can increase the expression of GLUT4. This is similar to 
another study that show curcumin increased expression of GLUT4, in 
which curcumin is one of the polyphenols similar to flavonoid [20]. 
The influence of EAFML on lipid profile indicated that this fraction 
can decrease cholesterol and triglycerides. The mechanism might 
have a correlation to the ability of flavonoids which are the main 
secondary metabolites of EAFML bound to pectin. Flavonoid 
cooperation with pectin can work at the level of intestine and liver 
to stimulate fat excretion and reduce fat absorption, which augments 
the direct activity on enzymes, involved in the regulation of 
carbohydrate and lipid metabolism [21]. 
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